Meta-analysis of commonly mutated genes in leptomeningeal carcinomatosis.
Bioinformatic analysis
Leptomeningeal carcinomatosis
Pathway enrichment analysis
Protein-protein interaction
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
01
2023
accepted:
28
03
2023
medline:
26
4
2023
pubmed:
25
4
2023
entrez:
25
04
2023
Statut:
epublish
Résumé
Leptomeningeal carcinomatosis (LMC) is a rare type of cancer that settles at the meninges through metastasis of non-small cell lung cancer (NSCLC), breast cancer and melanoma. The molecular mechanism underlying LMC is not known, therefore molecular studies investigating the development of LMC are needed. Here, we aimed to identify commonly mutated genes in LMC caused by NSCLC, breast cancer, and melanoma using an in-slico approach and their interactions using integrated bioinformatic approaches/tools in this meta-analysis. We conducted a meta-analysis using information from 16 studies that included different sequencing techniques of patients with LMC caused by three different primary cancers: breast cancer, NSCLC, and melanoma. All studies that assessed mutation information from patients with LMC were searched in PubMed, from their inception to February, 16 2022. Studies that performed NGS on LMC patients with NSCLC, breast cancer, or melanoma were included, while studies that did not apply NGS to CSF samples, did not provide information on altered genes, were reviews, editorials, or conference abstracts, or whose main goal was the detection of malignancies were all excluded. We identified commonly mutated genes in all three types of cancer. Next, we constructed a protein-protein interaction network, then performed pathway enrichment analysis. We searched National Institutes of Health (NIH) and Drug-Gene Interaction Database (DGIdb) to find candidate drugs. We found that In conclusion, a total of 96 mutated genes in LMC were investigated
Sections du résumé
Background
Leptomeningeal carcinomatosis (LMC) is a rare type of cancer that settles at the meninges through metastasis of non-small cell lung cancer (NSCLC), breast cancer and melanoma. The molecular mechanism underlying LMC is not known, therefore molecular studies investigating the development of LMC are needed. Here, we aimed to identify commonly mutated genes in LMC caused by NSCLC, breast cancer, and melanoma using an in-slico approach and their interactions using integrated bioinformatic approaches/tools in this meta-analysis.
Methods
We conducted a meta-analysis using information from 16 studies that included different sequencing techniques of patients with LMC caused by three different primary cancers: breast cancer, NSCLC, and melanoma. All studies that assessed mutation information from patients with LMC were searched in PubMed, from their inception to February, 16 2022. Studies that performed NGS on LMC patients with NSCLC, breast cancer, or melanoma were included, while studies that did not apply NGS to CSF samples, did not provide information on altered genes, were reviews, editorials, or conference abstracts, or whose main goal was the detection of malignancies were all excluded. We identified commonly mutated genes in all three types of cancer. Next, we constructed a protein-protein interaction network, then performed pathway enrichment analysis. We searched National Institutes of Health (NIH) and Drug-Gene Interaction Database (DGIdb) to find candidate drugs.
Results
We found that
Conclusion
In conclusion, a total of 96 mutated genes in LMC were investigated
Identifiants
pubmed: 37096065
doi: 10.7717/peerj.15250
pii: 15250
pmc: PMC10122459
doi:
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15250Informations de copyright
© 2023 Congur et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Nucleic Acids Res. 2021 Jan 8;49(D1):D1144-D1151
pubmed: 33237278
BMC Cancer. 2021 Feb 6;21(1):136
pubmed: 33549048
Curr Top Microbiol Immunol. 2010;347:21-41
pubmed: 20535651
Br J Cancer. 2012 Jan 17;106(2):397-404
pubmed: 22187033
Thorac Cancer. 2020 Mar;11(3):511-518
pubmed: 31989769
BMC Cancer. 2019 Feb 12;19(1):143
pubmed: 30755180
J Thorac Oncol. 2019 May;14(5):924-932
pubmed: 30659989
Front Immunol. 2019 Jan 29;10:71
pubmed: 30761139
J Thorac Oncol. 2018 Jul;13(7):1022-1027
pubmed: 29604399
Oncogene. 2014 Sep 18;33(38):4632-42
pubmed: 24141770
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Clin Transl Med. 2020 Dec;10(8):e246
pubmed: 33377642
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
Cancers (Basel). 2019 Dec 05;11(12):
pubmed: 31817502
Oncogene. 2004 Mar 25;23(13):2330-8
pubmed: 14743206
Anticancer Res. 2016 May;36(5):2243-9
pubmed: 27127129
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Cancers (Basel). 2019 Aug 09;11(8):
pubmed: 31404976
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Int J Mol Sci. 2016 Jul 05;17(7):
pubmed: 27399673
Cold Spring Harb Perspect Med. 2015 Apr 01;5(4):
pubmed: 25833940
ESMO Open. 2017 Oct 9;2(4):e000253
pubmed: 29067216
Trends Immunol. 2006 Nov;27(11):497-503
pubmed: 16997632
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635
pubmed: 29873738
Cancer. 2018 Jan 1;124(1):21-35
pubmed: 29165794
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Clin Chem. 2015 Mar;61(3):514-22
pubmed: 25605683
PLoS One. 2020 Mar 20;15(3):e0230306
pubmed: 32196516
Cancer Res. 2015 Dec 15;75(24):5341-54
pubmed: 26627007
Biochem Soc Trans. 2014 Aug;42(4):798-803
pubmed: 25109960
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546901
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell Death Dis. 2022 Nov 18;13(11):974
pubmed: 36400749
Cancer Cell. 2018 Mar 12;33(3):450-462.e10
pubmed: 29533785
Nat Protoc. 2019 Feb;14(2):482-517
pubmed: 30664679
Brain Pathol. 2012 Jan;22(1):89-98
pubmed: 22150924
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188438
pubmed: 32980466
J Biomed Biotechnol. 2011;2011:583929
pubmed: 21331359
Carcinogenesis. 2007 Feb;28(2):289-98
pubmed: 16861262
Front Oncol. 2021 Oct 04;11:701171
pubmed: 34671549
Science. 2019 Aug 9;365(6453):599-604
pubmed: 31395785
Oncotarget. 2021 Jun 22;12(13):1296-1308
pubmed: 34194626
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Front Oncol. 2021 Mar 25;11:644737
pubmed: 33842357
Cell Death Differ. 2013 Jul;20(7):898-909
pubmed: 23538418
Trends Cancer. 2020 Feb;6(2):98-110
pubmed: 32061310
Front Oncol. 2021 Feb 03;10:607149
pubmed: 33614491
Cancer Immunol Immunother. 2019 May;68(5):835-847
pubmed: 30406374
Thorac Cancer. 2020 Mar;11(3):588-593
pubmed: 31944608
Nat Cell Biol. 2007 May;9(5):573-80
pubmed: 17417627
Neurol Sci. 2015 Sep;36(9):1691-3
pubmed: 25990104
Clin Cancer Res. 2018 Jan 1;24(1):209-216
pubmed: 29030356
Ann Oncol. 2018 Apr 1;29(4):945-952
pubmed: 29346604
J Thorac Oncol. 2013 Feb;8(2):185-91
pubmed: 23328548
Cell. 2017 Mar 9;168(6):1101-1113.e13
pubmed: 28283064
Cell Death Differ. 2010 Dec;17(12):1807-15
pubmed: 20865012
Oncotarget. 2017 Dec 21;9(2):2705-2714
pubmed: 29416803
Cancer Biol Ther. 2019;20(4):562-570
pubmed: 30395779
JCO Precis Oncol. 2020 May 27;4:
pubmed: 32923889
Oncogene. 2018 Mar;37(10):1354-1368
pubmed: 29269867
NPJ Precis Oncol. 2021 Oct 8;5(1):90
pubmed: 34625644
Int J Mol Sci. 2015 May 06;16(5):10267-80
pubmed: 25955647
Clin Cancer Res. 2017 Sep 15;23(18):5480-5488
pubmed: 28606923
Int J Mol Sci. 2018 Nov 05;19(11):
pubmed: 30400561
J Neurooncol. 2016 May;128(1):93-100
pubmed: 26961773
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669